J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Moderna (NASDAQ:MRNA) on Thursday, setting a price target of $165, which is approximately 31.88% below the present share price of $242.23.
Kasimov expects Moderna to post earnings per share (EPS) of $8.27 for the fourth quarter of 2021.
The current consensus among 14 TipRanks analysts is for a Hold rating of shares in Moderna, with an average price target of $298.17.
The analysts price targets range from a high of $468 to a low of $86.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $4.97 billion and a net profit of $3.56 billion. The company's market cap is $98.21 billion.
According to TipRanks.com, J.P. Morgan analyst Cory Kasimov is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.0% and a 55.22% success rate.
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.